1
|
Campos LB, González Núñez AA, Palacio MJ, Ferro JP, Castañé PM, Ferrari L, Ossana NA. Acute and subchronic effects of ibuprofen on the ten spotted live-bearer fish Cnesterodon decemmaculatus (Jenyns, 1842). Chemosphere 2023; 340:139895. [PMID: 37604345 DOI: 10.1016/j.chemosphere.2023.139895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 08/15/2023] [Accepted: 08/18/2023] [Indexed: 08/23/2023]
Abstract
Ibuprofen (IBP) is an anti-inflammatory drug found in aquatic environments, potentially toxic for the biota. We exposed the test fish C. decemmaculatus to two environmentally relevant concentrations (50 and 100 μg IBP/L) for 4 and 12 d and evaluated the effect on some biomarkers. Micronucleus test, nuclear abnormality test and comet assay indicated cyto-genotoxicity at both concentrations and exposure periods. Oxidative stress and biochemical biomarkers were not affected, excepting muscle AChE activity for 4 d. Muscle metabolic biomarkers showed significant decrease in ETS, lipid and protein content, while carbohydrate content was not affected. The CEA index increased at the lower IBP concentration for 4 and 12 d, possibly due to changes in body energy reserves. A full-factorial GLM performed to assess the effects of IBP and exposure times showed that the metabolic and genotoxicity biomarkers were the most sensitive to IBP toxicity, mainly at 50 μg IBP/L for 4 d.
Collapse
Affiliation(s)
- L B Campos
- Programa de Ecofisiología Aplicada (PRODEA) Instituto de Ecología y Desarrollo Sustentable (INEDES, CONICET-UNLu), Departamento de Cs. Básicas, Universidad Nacional de Luján, B6700ZBA, Luján, Argentina
| | - A A González Núñez
- Programa de Ecofisiología Aplicada (PRODEA) Instituto de Ecología y Desarrollo Sustentable (INEDES, CONICET-UNLu), Departamento de Cs. Básicas, Universidad Nacional de Luján, B6700ZBA, Luján, Argentina
| | - M J Palacio
- Programa de Ecofisiología Aplicada (PRODEA) Instituto de Ecología y Desarrollo Sustentable (INEDES, CONICET-UNLu), Departamento de Cs. Básicas, Universidad Nacional de Luján, B6700ZBA, Luján, Argentina
| | - J P Ferro
- Programa de Ecofisiología Aplicada (PRODEA) Instituto de Ecología y Desarrollo Sustentable (INEDES, CONICET-UNLu), Departamento de Cs. Básicas, Universidad Nacional de Luján, B6700ZBA, Luján, Argentina
| | - P M Castañé
- Programa de Ecofisiología Aplicada (PRODEA) Instituto de Ecología y Desarrollo Sustentable (INEDES, CONICET-UNLu), Departamento de Cs. Básicas, Universidad Nacional de Luján, B6700ZBA, Luján, Argentina
| | - L Ferrari
- Programa de Ecofisiología Aplicada (PRODEA) Instituto de Ecología y Desarrollo Sustentable (INEDES, CONICET-UNLu), Departamento de Cs. Básicas, Universidad Nacional de Luján, B6700ZBA, Luján, Argentina
| | - N A Ossana
- Programa de Ecofisiología Aplicada (PRODEA) Instituto de Ecología y Desarrollo Sustentable (INEDES, CONICET-UNLu), Departamento de Cs. Básicas, Universidad Nacional de Luján, B6700ZBA, Luján, Argentina.
| |
Collapse
|
2
|
Pinotti L, Ferrari L, Fumagalli F, Luciano A, Manoni M, Mazzoleni S, Govoni C, Rulli MC, Lin P, Bee G, Tretola M. Review: Pig-based bioconversion: the use of former food products to keep nutrients in the food chain. Animal 2023; 17 Suppl 2:100918. [PMID: 37544840 DOI: 10.1016/j.animal.2023.100918] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Revised: 07/14/2023] [Accepted: 07/17/2023] [Indexed: 08/08/2023] Open
Abstract
The primary challenge of agriculture and livestock production is to face the growing competition between food, feed, fibre, and fuel, converting them from resource-intensive to resource-efficient. A circular economy approach, using agricultural by-products/co-products, in the livestock production system would allow to reduce, reuse, and redistribute the resources. Former food products (FFPs), also named ex-foods, could represent a valid option in strengthening resilience in animal nutrition. FFPs have a promising potential to be included regularly in animal diets due to their nutritive value, although their potential in animal nutrition remains understudied. A thorough investigation of the compositional and dietary features, thus, is essential to provide new and fundamental insights to effectively reuse FFPs as upgraded products for swine nutrition. Safety aspects, such as the microbial load or the presence of packaging remnants, should be considered with caution. Here, with a holistic approach, we review several aspects of FFPs and their use as feed ingredients: the nutritional and functional evaluation, the impact of the inclusion of FFPs in pigs' diet on growth performance and welfare, and further aspects related to safety and sustainability of FFPs.
Collapse
Affiliation(s)
- L Pinotti
- Department of Veterinary Medicine and Animal Science (DIVAS), University of Milan, 26900 Lodi, Italy.
| | - L Ferrari
- Department of Veterinary Medicine and Animal Science (DIVAS), University of Milan, 26900 Lodi, Italy
| | - F Fumagalli
- Department of Veterinary Medicine and Animal Science (DIVAS), University of Milan, 26900 Lodi, Italy
| | - A Luciano
- Department of Veterinary Medicine and Animal Science (DIVAS), University of Milan, 26900 Lodi, Italy
| | - M Manoni
- Department of Veterinary Medicine and Animal Science (DIVAS), University of Milan, 26900 Lodi, Italy
| | - S Mazzoleni
- Department of Veterinary Medicine and Animal Science (DIVAS), University of Milan, 26900 Lodi, Italy
| | - C Govoni
- Department of Civil and Environmental Engineering (DICA), Politecnico di Milano, 20133 Milan, Italy
| | - M C Rulli
- Department of Civil and Environmental Engineering (DICA), Politecnico di Milano, 20133 Milan, Italy
| | - P Lin
- Department of Veterinary Medicine and Animal Science (DIVAS), University of Milan, 26900 Lodi, Italy; Agroscope, Institute for Livestock Production, 1725 Posieux, Switzerland
| | - G Bee
- Agroscope, Institute for Livestock Production, 1725 Posieux, Switzerland
| | - M Tretola
- Department of Veterinary Medicine and Animal Science (DIVAS), University of Milan, 26900 Lodi, Italy; Agroscope, Institute for Livestock Production, 1725 Posieux, Switzerland
| |
Collapse
|
3
|
Kaiser M, Issa N, Issa N, Ferrari L, Jimenez J. 589 Platelet rich plasma combination therapies for treatment of androgenetic alopecia: A systematic review. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Feinberg PA, Becker SC, Chung L, Ferrari L, Stellwagen D, Anaclet C, Durán-Laforet V, Faust TE, Sumbria RK, Schafer DP. Elevated TNF-α Leads to Neural Circuit Instability in the Absence of Interferon Regulatory Factor 8. J Neurosci 2022; 42:6171-6185. [PMID: 35790400 PMCID: PMC9374154 DOI: 10.1523/jneurosci.0601-22.2022] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2022] [Revised: 06/03/2022] [Accepted: 06/24/2022] [Indexed: 11/21/2022] Open
Abstract
Interferon regulatory factor 8 (IRF8) is a transcription factor necessary for the maturation of microglia, as well as other peripheral immune cells. It also regulates the transition of microglia and other immune cells to a pro-inflammatory phenotype. Irf8 is also a known risk gene for multiple sclerosis and lupus, and it has recently been shown to be downregulated in schizophrenia. While most studies have focused on IRF8-dependent regulation of immune cell function, little is known about how it impacts neural circuits. Here, we show by RNAseq from Irf8 -/- male and female mouse brains that several genes involved in regulation of neural activity are dysregulated. We then show that these molecular changes are reflected in heightened neural excitability and a profound increase in susceptibility to lethal seizures in male and female Irf8 -/- mice. Finally, we identify that TNF-α is elevated specifically in microglia in the CNS, and genetic or acute pharmacological blockade of TNF-α in the Irf8 -/- CNS rescued the seizure phenotype. These results provide important insights into the consequences of IRF8 signaling and TNF-α on neural circuits. Our data further suggest that neuronal function is impacted by loss of IRF8, a factor involved in neuropsychiatric and neurodegenerative diseases.SIGNIFICANCE STATEMENT Here, we identify a previously unknown and key role for interferon regulator factor 8 (IRF8) in regulating neural excitability and seizures. We further determine that these effects on neural circuits are through elevated TNF-α in the CNS. As IRF8 has most widely been studied in the context of regulating the development and inflammatory signaling in microglia and other immune cells, we have uncovered a novel function. Further, IRF8 is a risk gene for multiple sclerosis and lupus, IRF8 is dysregulated in schizophrenia, and elevated TNF-α has been identified in a multitude of neurologic conditions. Thus, elucidating these IRF8 and TNF-α-dependent effects on brain circuit function has profound implications for understanding underlying, therapeutically relevant mechanisms of disease.
Collapse
Affiliation(s)
- Philip A Feinberg
- Department of Neurobiology, Brudnick Neuropsychiatric Research Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605
| | - Shannon C Becker
- Department of Neurobiology, Brudnick Neuropsychiatric Research Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605
| | - Leeyup Chung
- Department of Neurobiology, Brudnick Neuropsychiatric Research Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605
| | - Loris Ferrari
- Department of Neurobiology, Brudnick Neuropsychiatric Research Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605
| | - David Stellwagen
- Department of Neurology and Neurosurgery, Centre for Research in Neuroscience, Research Institute of the McGill University Health Center, Montreal, Quebec Canada H3G 1A4
| | - Christelle Anaclet
- Department of Neurobiology, Brudnick Neuropsychiatric Research Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605
| | - Violeta Durán-Laforet
- Department of Neurobiology, Brudnick Neuropsychiatric Research Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605
| | - Travis E Faust
- Department of Neurobiology, Brudnick Neuropsychiatric Research Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605
| | - Rachita K Sumbria
- Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, California 92618
- Department of Neurology, University of California, Irvine, California 92868
| | - Dorothy P Schafer
- Department of Neurobiology, Brudnick Neuropsychiatric Research Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605
| |
Collapse
|
5
|
Pavlovsky A, Fiad L, Fernandez I, Prates V, Kurgansky N, Cerutti A, Sackman F, Negri F, Zoppegno L, Negri P, Remaggi G, Ferrari L, Mariano R, Guanchiale L, Maradei J, Rudoy S, Giuliani F, Roveri E, Enrico A, Zabaljauregui S, Cabrejo M, Gumpel C, Quartara A, Gonzalez CM, Varela A, Riddick M, Pavlovsky S. PET‐ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH‐05 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.108_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | - L. Fiad
- Hospital Italiano La Plata Hematology Buenos Aires Argentina
| | | | - V. Prates
- Hospital Italiano La Plata Hematology Buenos Aires Argentina
| | | | - A. Cerutti
- IDHEA Clínica Hematológica Hematology Rosario, Santa Fe Argentina
| | - F. Sackman
- Fundaleu Hematology Buenos Aires Argentina
| | - F. Negri
- Instituto Privado de Hematología y Hemoterapia Hematology Paraná, Entre Ríos Argentina
| | - L. Zoppegno
- HIGA General José de San Martín La Plata Hematology Buenos Aires Argentina
| | - P. Negri
- Instituto Privado de Hematología y Hemoterapia Hematology Paraná, Entre Ríos Argentina
| | - G. Remaggi
- Fundaleu Hematology Buenos Aires Argentina
| | - L. Ferrari
- Fundaleu Hematology Buenos Aires Argentina
| | - R. Mariano
- Hospital San Martín Hematology Paraná, Entre Ríos, California Argentina
| | - L. Guanchiale
- Hospital Universitario Privado de Córdoba Hematology Córdoba Argentina
| | - J. Maradei
- Hospital Municipal Dr. E. Ferreyra Hematology Necochea, Buenos Aires Argentina
| | - S. Rudoy
- Clínica Modelo de Morón Hematology Buenos Aires Argentina
| | | | - E. Roveri
- Hospital Provincial del Centenario Hematology Rosario, Santa Fe Argentina
| | - A. Enrico
- Hospital Italiano La PLata Hematology Buenos Aires Argentina
| | - S. Zabaljauregui
- Instituto de Investigaciones Hematológicas Mariano R. Castex Hematology Buenos Aires Argentina
| | - M. Cabrejo
- Sanatorio Municipal Julio Méndez Hematology Buenos Aires Argentina
| | - C. Gumpel
- Sanatorio Plaza Hematology Rosario, Santa Fe Argentina
| | - A. Quartara
- Hospital Provincial del Centenario Hematology Rosario, Santa Fe Argentina
| | - C. M. Gonzalez
- Instituto de Investigaciones Hematológicas Mariano R. Castex Hematology Buenos Aires Argentina
| | - A. Varela
- Sanatorio Las Lomas Hematology Buenos Aires Argentina
| | - M. Riddick
- Departamento de Matematicas‐Facultad de Ciencias Exactas‐ UNLP‐CONICET Mathematics Buenos Aires Argentina
| | | |
Collapse
|
6
|
Cristofolini M, De Luca R, Venner A, Ferrari L, Grace K, Fuller P, Arrigoni E. 074 Basal Forebrain GABAergic Neurons Promote Arousal by Disinhibiting the Orexin Neurons via Local GABAergic Interneurons. Sleep 2021. [DOI: 10.1093/sleep/zsab072.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Optogenetic and chemogenetic studies have shown that activation of basal forebrain (BF) GABAergic neurons rapidly wakes up mice from non-REM (NREM) sleep. These wake-promoting responses have been attributed to BF GABAergic neurons projecting to the cerebral cortex and more specifically to the inhibition of cortical fast-spiking interneurons. Tracing studies have however found that BF GABAergic neurons also densely innervate the lateral hypothalamus (LH) perifornical area, although the role of this pathway in behavioral state control remains mostly unexplored.
Methods
We conducted in vivo and in vitro optogenetic studies. We selectively expressed channelrhodopsin-2 (ChR2) in BF GABAergic neurons by injecting a cre-dependent viral vector encoding for ChR2 into the BF of VGAT-cre mice. We photostimulated the BF GABAergic input to the LH with optical fibers placed into the LH of EEG instrumented mice. For in vitro recordings we expressed ChR2 in BF GABAergic neurons and we fluorescently labeled orexin or LH GABAergic neurons. We recorded in brain slices from identified orexin neurons or GABA neurons while photostimulating the BF GABAergic input.
Results
Optogenetic stimulation of the BF GABAergic fibers in the LH produced rapid arousals from NREM sleep. The same stimulation however did not wake up the mice if they were in REM sleep. We conducted additional studies in brain slices to identify the postsynaptic neurons in the LH targeted by the BF GABAergic input. We found that while optogenetic stimulation of the BF GABAergic input did not produce opto-evoked synaptic responses in the orexin neurons, it produced short-latency opto-evoked inhibitory postsynaptic currents (IPSCs) in LH GABAergic neurons. These opto-evoked IPSCs were GABAA receptor-mediated and were maintained in tetrodotoxin (TTX) indicating monosynaptic connectivity. We have previously found that orexin neurons are inhibited by local LH GABAergic neurons. Our hypothesis is that these local GABAergic interneurons are the target of the BF GABAergic arousal input.
Conclusion
BF GABAergic neurons drive arousal through projections to the LH. We propose that this arousal response is due to the inhibition of local GABAergic interneurons which in turn disinhibit the LH wake-promoting neurons including the orexin neurons.
Support (if any)
NS091126 and HL149630
Collapse
Affiliation(s)
| | - Roberto De Luca
- Beth Israel Deaconess Medical Center, Harvard Medical School
| | | | | | | | | | | |
Collapse
|
7
|
Macchi C, Iodice S, Persico N, Ferrari L, Cantone L, Greco MF, Ischia B, Dozio E, Corsini A, Sirtori CR, Ruscica M, Bollati V. Maternal exposure to air pollutants, PCSK9 levels, fetal growth and gestational age - An Italian cohort. Environ Int 2021; 149:106163. [PMID: 33556817 DOI: 10.1016/j.envint.2020.106163] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Revised: 08/24/2020] [Accepted: 09/23/2020] [Indexed: 06/12/2023]
Abstract
OBJECTIVE Exposure to airborne pollutants during pregnancy appears to be associated with uterine growth restriction and adverse neonatal outcome. Proprotein convertase subtilisin/kexin type (PCSK9), the key modulator of low-density lipoprotein (LDL) metabolism, increases following particulate matter (PM10) exposure. Because maternal cholesterol is required for fetal growth, PCSK9 levels could be used to evaluate the potential impact of airborne pollutants on fetal growth. DESIGN A cohort of 134 healthy women during early pregnancy (11-12 weeks of gestational age) was studied. RESULTS A significant association between circulating PCSK9 levels and three tested air pollutants (PM10, PM2.5, nitric oxide (NO2)) was found. Of importance, gestational age at birth was reduced by approximately 1 week for each 100 ng/mL rise in circulating PCSK9 levels, an effect that became more significant at the highest quartile of PM2.5 (with a 1.8 week advance in delivery date for every 100 ng/mL rise in circulating PCSK9; p for interaction = 0.026). This finding was supported by an elevation of the odds ratio for urgent cesarean delivery for each 100 ng/mL rise in PCSK9 (2.99, 95% CI, 1.22-6.57), similar trends being obtained for PM10 and NO2. CONCLUSIONS The association between exposure to air pollutants during pregnancy and elevation in PCSK9 advances our understanding of the unforeseen influences of environmental exposure in terms of pregnancy associated disorders.
Collapse
Affiliation(s)
- C Macchi
- Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Italy
| | - S Iodice
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
| | - N Persico
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy; Department of Obstetrics and Gynecology 'L. Mangiagalli', Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - L Ferrari
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
| | - L Cantone
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
| | - M F Greco
- Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Italy
| | - B Ischia
- Department of Obstetrics and Gynecology 'L. Mangiagalli', Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - E Dozio
- Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy
| | - A Corsini
- Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Italy; IRCCS MultiMedica, Sesto S. Giovanni, Milan, Italy
| | - C R Sirtori
- Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Italy
| | - M Ruscica
- Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Italy.
| | - V Bollati
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.
| |
Collapse
|
8
|
Galeotti G, De Marchi F, Hamzehpoor E, MacLean O, Rajeswara Rao M, Chen Y, Besteiro LV, Dettmann D, Ferrari L, Frezza F, Sheverdyaeva PM, Liu R, Kundu AK, Moras P, Ebrahimi M, Gallagher MC, Rosei F, Perepichka DF, Contini G. Synthesis of mesoscale ordered two-dimensional π-conjugated polymers with semiconducting properties. Nat Mater 2020; 19:874-880. [PMID: 32424372 DOI: 10.1038/s41563-020-0682-z] [Citation(s) in RCA: 104] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Accepted: 04/14/2020] [Indexed: 05/08/2023]
Abstract
Two-dimensional materials with high charge carrier mobility and tunable band gaps have attracted intense research effort for their potential use in nanoelectronics. Two-dimensional π-conjugated polymers constitute a promising subclass because the band structure can be manipulated by varying the molecular building blocks while preserving key features such as Dirac cones and high charge mobility. The major barriers to the application of two-dimensional π-conjugated polymers have been the small domain size and high defect density attained in the syntheses explored so far. Here, we demonstrate the fabrication of mesoscale ordered two-dimensional π-conjugated polymer kagome lattices with semiconducting properties, Dirac cone structures and flat bands on Au(111). This material has been obtained by combining a rigid azatriangulene precursor and a hot dosing approach, which favours molecular diffusion and eliminates voids in the network. These results open opportunities for the synthesis of two-dimensional π-conjugated polymer Dirac cone materials and their integration into devices.
Collapse
Affiliation(s)
- G Galeotti
- Centre Energie, Matériaux et Télécommunications, Institut National de la Recherche Scientifique, Varennes, Québec, Canada
- Istituto di Struttura della Materia, CNR, Roma, Italy
- Deutsches Museum, München, Germany
| | - F De Marchi
- Centre Energie, Matériaux et Télécommunications, Institut National de la Recherche Scientifique, Varennes, Québec, Canada
| | - E Hamzehpoor
- Department of Chemistry, McGill University, Montreal, Québec, Canada
| | - O MacLean
- Centre Energie, Matériaux et Télécommunications, Institut National de la Recherche Scientifique, Varennes, Québec, Canada
| | - M Rajeswara Rao
- Department of Chemistry, McGill University, Montreal, Québec, Canada
| | - Y Chen
- Department of Chemistry, McGill University, Montreal, Québec, Canada
| | - L V Besteiro
- Centre Energie, Matériaux et Télécommunications, Institut National de la Recherche Scientifique, Varennes, Québec, Canada
- Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu, China
| | - D Dettmann
- Centre Energie, Matériaux et Télécommunications, Institut National de la Recherche Scientifique, Varennes, Québec, Canada
- Istituto di Struttura della Materia, CNR, Roma, Italy
| | - L Ferrari
- Istituto di Struttura della Materia, CNR, Roma, Italy
| | - F Frezza
- Istituto di Struttura della Materia, CNR, Roma, Italy
- Department of Physics, University of Tor Vergata, Rome, Italy
| | | | - R Liu
- Department of Physics, Lakehead University, Thunder Bay, Ontario, Canada
| | - A K Kundu
- Istituto di Struttura della Materia, CNR, Trieste, Italy
| | - P Moras
- Istituto di Struttura della Materia, CNR, Trieste, Italy
| | - M Ebrahimi
- Centre Energie, Matériaux et Télécommunications, Institut National de la Recherche Scientifique, Varennes, Québec, Canada
- Department of Chemistry, Lakehead University, Thunder Bay, Ontario, Canada
| | - M C Gallagher
- Department of Physics, Lakehead University, Thunder Bay, Ontario, Canada.
| | - F Rosei
- Centre Energie, Matériaux et Télécommunications, Institut National de la Recherche Scientifique, Varennes, Québec, Canada.
| | - D F Perepichka
- Department of Chemistry, McGill University, Montreal, Québec, Canada.
| | - G Contini
- Istituto di Struttura della Materia, CNR, Roma, Italy.
- Department of Physics, University of Tor Vergata, Rome, Italy.
| |
Collapse
|
9
|
Gennari M, Bonetti M, Volpi S, Grandelli M, Cardinali A, Maffezzoni F, Ferrari L, Zubbi S, Marchetti F, Scollato A, D'Adda C. Psycho-social characteristics in patients with discopathy: Quality of Life, coping strategy and mood state. J BIOL REG HOMEOS AG 2020; 34:37-45. SPECIAL ISSUE: OZONE THERAPY. [PMID: 33176416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The pathologies of the musculoskeletal apparatus are the most common cause of chronic diseases, with a huge impact on people and society. Scientific literature has discovered how experiencing chronic pain directly affects peoples' well-being, lifestyle, social relationships and can also cause psychological distress. The present study aims to investigate pain experience in patients with hernias or protrusions of the cervical and lumbosacral tract on a sample of 120 patients, recruited from patients of Poliambulatorio Oberdan, medical centre in Brescia (Italy) specialized in physical rehabilitation and CT-guided oxygen ozone therapy. In a bio-psychosocial perspective, the research aimed to investigate how the perception of pain, the mood state associated with it, the coping strategies adopted and the quality of life differ according to each patient's gender and to the more or less prolonged use of pain medication. The data were collected by means of medical and psychological anamnestic interviews and self-report tests (WHOQOL-BREF, COPE-NVI, POMS). The quantitative analysis, carried out through SPSS 25 (2017) software, showed how functional impairment of one's autonomy (walking, driving) affects mood states. In particular, the female sample expressed a more deflected mood, despite the greater use of relational and/or transcendent support (coping strategies) compared to men. The study suggests that the greater impairment of the moods of women can be attributed both to the caregiving role they play, which often results in a greater fatigue and difficulties in redefining this role following the algic condition, and more general differences in the expression of suffering, which, on a cultural level, sees men emotionally coerced. The analysis also shows how taking pain medication for a long period of time has a negative impact on the quality of life. The results suggest that the patients treated with analgesic therapy tend to adopt avoidant coping styles, which usually escalate into postponement of the time when dealing with a stressful situation and, if used in the long run, may lead to worsening health condition.
Collapse
Affiliation(s)
- M Gennari
- Psychologist, Associate Professor in Clinical Psychology, Catholic University of the Sacred Heart (Brescia), Department of Psychology, Italy
| | - M Bonetti
- Neuroradiologist, Chief medical officer Poliambulatorio Oberdan, Brescia, Italy
| | - S Volpi
- Neuroradiologist, Chief medical officer Poliambulatorio Oberdan, Brescia, Italy
| | - M Grandelli
- Neuroradiologist, Chief medical officer Poliambulatorio Oberdan, Brescia, Italy
| | - A Cardinali
- Neuroradiologist, Chief medical officer Poliambulatorio Oberdan, Brescia, Italy
| | - F Maffezzoni
- Neuroradiologist, Chief medical officer Poliambulatorio Oberdan, Brescia, Italy
| | - L Ferrari
- Neuroradiologist, Chief medical officer Poliambulatorio Oberdan, Brescia, Italy
| | - S Zubbi
- Neuroradiologist, Chief medical officer Poliambulatorio Oberdan, Brescia, Italy
| | - F Marchetti
- Neuroradiologist, Chief medical officer Poliambulatorio Oberdan, Brescia, Italy
| | - A Scollato
- Neuroradiologist, Chief medical officer Poliambulatorio Oberdan, Brescia, Italy
| | - C D'Adda
- Nutritionist doctor, Poliambulatorio Oberdan, Brescia, Italy
| |
Collapse
|
10
|
Giardino L, Bidossi A, Del Fabbro M, Savadori P, Maddalone M, Ferrari L, Ballal NV, Das S, Rao BSS. Antimicrobial activity, toxicity and accumulated hard‐tissue debris (AHTD) removal efficacy of several chelating agents. Int Endod J 2020; 53:1093-1110. [DOI: 10.1111/iej.13314] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Revised: 04/22/2020] [Accepted: 04/24/2020] [Indexed: 12/18/2022]
Affiliation(s)
- L. Giardino
- School of Dentistry University of Catanzaro Magna Graecia Catanzaro Italy
| | - A. Bidossi
- Laboratory of Clinical Chemistry and Microbiology IRCCS Orthopedic Institute Galeazzi Milano Italy
| | - M. Del Fabbro
- Department of Biomedical Surgical and Dental Sciences Università degli Studi di Milano Milano Italy
- IRCCS Orthopedic Institute Galeazzi Milano Italy
| | - P. Savadori
- IRCCS Orthopedic Institute Galeazzi Milano Italy
| | - M. Maddalone
- Department of Medicine and Surgery University of Milano‐Bicocca Monza Italy
| | - L. Ferrari
- Department of Medicine and Surgery University of Milano‐Bicocca Monza Italy
| | - N. V. Ballal
- Department of Conservative Dentistry and Endodontics Manipal College of Dental Sciences, Manipal Academy of Higher Education Manipal Karnataka India
| | - S. Das
- Department of Radiation Biology and Toxicology Manipal School of Life Sciences Manipal Academy of Higher Education Manipal Karnataka India
| | - B. S. S. Rao
- Department of Radiation Biology and Toxicology Manipal School of Life Sciences Manipal Academy of Higher Education Manipal Karnataka India
| |
Collapse
|
11
|
Abstract
Exposure to airborne particulate matter (PM) has been associated with detrimental health effects. DNA methylation represents the most well-studied epigenetic factor among the possible mechanisms underlying this association. Interestingly, changes of DNA methylation in response to environmental stimuli are being considered for their role in the pathogenic mechanism, but also as mediators of the body adaptation to air pollutants.Several studies have evaluated both global and gene-specific methylation in relation to PM exposure in different clinical conditions and life stages. The purpose of the present literature review is to evaluate the most relevant and recent studies in the field in order to analyze the available evidences on long- and short-term PM exposure and DNA methylation changes, with a particular focus on the different life stages when the alteration occurs. PM exposure modulates DNA methylation affecting several biological mechanisms with marked effects on health, especially during susceptible life stages such as pregnancy, childhood, and the older age.Although many cross-sectional investigations have been conducted so far, only a limited number of prospective studies have explored the potential role of DNA methylation. Future studies are needed in order to evaluate whether these changes might be reverted.
Collapse
Affiliation(s)
- L Ferrari
- EPIGET-Epidemiology, Epigenetics and Toxicology Lab, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, via San Barnaba 8, 20122, Milan, Italy
| | - M Carugno
- EPIGET-Epidemiology, Epigenetics and Toxicology Lab, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, via San Barnaba 8, 20122, Milan, Italy
| | - V Bollati
- EPIGET-Epidemiology, Epigenetics and Toxicology Lab, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, via San Barnaba 8, 20122, Milan, Italy.
| |
Collapse
|
12
|
Saleri R, Cavalli V, Ferrari L, Ogno G, Canelli E, Martelli P, Borghetti P. Modulation of the somatotropic axis, adiponectin and cytokine secretion during highly pathogenic porcine reproductive and respiratory syndrome virus type 1 (HP-PRRSV-1) infection. Res Vet Sci 2019; 124:263-269. [PMID: 31003008 DOI: 10.1016/j.rvsc.2019.04.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Revised: 04/09/2019] [Accepted: 04/10/2019] [Indexed: 01/07/2023]
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) is known to be clinically responsible for reproductive failure in sows and post-weaning respiratory disease in growing piglets. During the last years, highly pathogenic PRRSV isolates have been discovered. In Italy, a PRRSV-1 subtype 1 strain (namely PR40/2014) characterized by high pathogenicity was isolated and experimental infection was characterized in terms of virological/clinical features and immune modulation (Canelli et al., 2017; Ferrari et al., 2018). The present study was performed in 4-week-old pigs experimentally infected with the highly pathogenic PRRSV1_PR40/2014 (HP-PR40) or with the conventional PRRSV1_PR11/2014 (PR11). The aim was to evaluate the interrelation between plasmatic hormones and cytokines in infected pigs compared to uninfected controls in order to address potential effects on the course of an experimental infection. The time-related changes of growth hormone (GH), insulin-like growth factor-1 (IGF-1), adiponectin, interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels appear to be modulated by the infection depending on the PRRSV isolate (HP-PR40 vs. PR11). In particular, in HP-PR40 infected animals, the association between high GH levels and viremia may testify the need to block the anabolic action of GH in order to shift available energy towards the immune response. This need appeared to be delayed in PR11 animals, given the lower pathogenicity of the isolate. Adiponectin, IL-6 and TNF-α course supports the hypothesis of GH resistance mechanisms to guarantee homeostasis in HP-PR40 animals and underlines the key role of energy availability in events leading to an effective response to the virus.
Collapse
Affiliation(s)
- R Saleri
- Department of Veterinary Science, University of Parma, Strada del Taglio, 10, 43126 Parma, Italy.
| | - V Cavalli
- Department of Veterinary Science, University of Parma, Strada del Taglio, 10, 43126 Parma, Italy
| | - L Ferrari
- Department of Veterinary Science, University of Parma, Strada del Taglio, 10, 43126 Parma, Italy
| | - G Ogno
- Department of Veterinary Science, University of Parma, Strada del Taglio, 10, 43126 Parma, Italy
| | - E Canelli
- Department of Veterinary Science, University of Parma, Strada del Taglio, 10, 43126 Parma, Italy
| | - P Martelli
- Department of Veterinary Science, University of Parma, Strada del Taglio, 10, 43126 Parma, Italy
| | - P Borghetti
- Department of Veterinary Science, University of Parma, Strada del Taglio, 10, 43126 Parma, Italy
| |
Collapse
|
13
|
Broughton N, Ferrari L, Head J. Surrogate decision makers and acute care. Anaesthesia 2019; 74:394-395. [PMID: 30734952 DOI: 10.1111/anae.14549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | - L Ferrari
- Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK
| | - J Head
- West Suffolk NHS Foundation Trust, Bury St Edmunds, UK
| |
Collapse
|
14
|
|
15
|
Zilembo N, Buzzoni R, Celio L, Noberasco C, Ferrari L, Laffranchi A, Vicario G, Dolci S, Bajetta E. Formestane as Treatment of Advanced Breast Cancer in Elderly Women. Tumori 2018; 80:433-7. [PMID: 7900232 DOI: 10.1177/030089169408000605] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and background The number of elderly people is increasing, and the proportion of breast cancer in female cancer patients older than 65 years is 26%. In elderly patients, hormone therapy is widely accepted as the treatment of choice, because of its efficacy and good tolerability compared to chemotherapy. The aim of this study was to evaluate the endocrinologic and clinical activity of formestane (4-hydroxyandrostenedione), a selective aromatase inhibitor, in elderly patients with advanced breast cancer. Methods Thirty-five patients older than 65 years, selected from a larger group, were given formestane (250 mg or 500 mg i.m. fortnightly). Patients were evaluable for tumor response after 4 doses of formestane. Blood samples were collected to evaluate E2, FSH, LH, SHBG and DHEAS serum levels at baseline and after 2, 4, 8,12 and 24 weeks. Results Thirty patients had PS ≤ 1 (ECOG) and only 5 patients had PS = 2. Twenty-six patients were ER positive. Previous hormonal treatment for metastatic disease had been given to 17 patients; only 1 case had received chemotherapy. The overall response rate was 51% (95% C.I. 35–67%) and the median response duration was 9.5 months. Three complete responses were observed on viscera. The best responses were obtained on soft tissues (59%); on bone and viscera the response was respectively 45% and 47%. Local and systemic tolerability was highly satisfactory. Formestane induced prolonged suppression of E2 levels in all of the patients, and a significant reduction in SHBG levels was also observed from month 2 onward. A statistically significant ( P = 0.0001) rise in serum FSH was also observed during the therapy. Conclusions The study showed that formestane induced a long-lasting suppression of E2 levels and a satisfactory overall response. In our opinion, the drug is an effective and well-tolerated approach in the management of advanced breast cancer in elderly patients.
Collapse
Affiliation(s)
- N Zilembo
- Medical Oncology Division B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Gambacorti-Passerini ZM, Penati C, Carli A, Accordino F, Ferrari L, Berghella V, Locatelli A. Vaginal birth after prior myomectomy. Eur J Obstet Gynecol Reprod Biol 2018; 231:198-203. [PMID: 30396109 DOI: 10.1016/j.ejogrb.2018.10.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2018] [Revised: 09/28/2018] [Accepted: 10/01/2018] [Indexed: 12/31/2022]
Abstract
OBJECTIVE The aim of this retrospective cohort study was to evaluate the obstetrical and perinatal outcomes of vaginal birth in case of pregnancies achieved after prior myomectomy. We also analyzed how operative characteristics at the time of surgery might influence the choice of obstetricians about mode of delivery. STUDY DESIGN We analyzed retrospectively all women who underwent laparoscopic (LPS) or laparotomic (LPT) myomectomy between January 2002 and December 2014, in a network of three Institutions belonging to the University of Milano Bicocca, Italy. Women were contacted by phone interview and only cases with available follow-up data and who had a subsequent pregnancy were included. Operative characteristics and subsequent obstetrical outcomes were recorded and analyzed. RESULTS 469 women who underwent myomectomy were contacted by phone interview, and 152 pregnancies were achieved after surgery, 96 after LPS and 56 after LPT. A total of 110 pregnancies ended in deliveries at ≥24 weeks. Seventy-three (66.4%) women had trial of labor after myomectomy (TOLAM), while 24 (21.8%) had a planned cesarean delivery (CD). Sixty-six (90.4%) of the TOLAM cases successfully accomplished vaginal delivery. No cases of uterine rupture (UR) were reported, and all deliveries ended in live births. The incidence of Neonatal Intensive Care Unit admission was 14.5% (16/110), with no cases of perinatal death. Comparing the surgical details at the time of myomectomy, the incidence of uterine cavity entered was significantly higher in planned CD group compared to TOLAM cases (p < 0.001). No other significant difference between the two groups was reported. CONCLUSIONS A successful vaginal delivery was accomplished by 90.4% of women who had TOLAM, without any case of UR or severe maternal and perinatal complications. TOLAM may be considered and offered as feasible and relatively safe option. Obstetricians' attitude toward mode of delivery after prior myomectomy seems to be influenced by the reported entry into the uterine cavity at the time of surgery.
Collapse
Affiliation(s)
| | - C Penati
- Department of Obstetrics and Gynecology, Carate Brianza Hospital, ASST Vimercate, Italy
| | - A Carli
- University of Milano Bicocca, Milan, Italy; Department of Obstetrics and Gynecology, San Gerardo Hospital - FMBBM, Monza, Italy
| | - F Accordino
- University of Milano Bicocca, Milan, Italy; Department of Obstetrics and Gynecology, San Gerardo Hospital - FMBBM, Monza, Italy
| | - L Ferrari
- Department of Obstetrics and Gynecology, San Gerardo Hospital, ASST Monza, Italy
| | - V Berghella
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, United States
| | - A Locatelli
- University of Milano Bicocca, Milan, Italy; Department of Obstetrics and Gynecology, Carate Brianza Hospital, ASST Vimercate, Italy
| |
Collapse
|
17
|
Santini D, Brandi G, Aprile G, Russano M, Cereda S, Leone F, Lonardi S, Fornaro L, Scartozzi M, Silvestris N, Barni S, Pantano F, Vincenzi B, Palloni A, Frega G, Casagrande M, Ferrari L, Dadduzio V, Intini R, Filippi R, Vasile E, Vivaldi C, Faloppi L, Brunetti O, Reni M, Aglietta M, Tonini G. Bone metastases in biliary cancers: A multicenter retrospective survey. J Bone Oncol 2018; 12:33-37. [PMID: 30042924 PMCID: PMC6054714 DOI: 10.1016/j.jbo.2017.11.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2017] [Revised: 11/18/2017] [Accepted: 11/24/2017] [Indexed: 10/24/2022] Open
Abstract
•Natural history of biliary cancers metastatic to bone•The role of skeletal events in patients with biliary cancer•Biliary cancer and bone metastases: role of bisphosphonates.
Collapse
Affiliation(s)
- D Santini
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - G Brandi
- Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| | - G Aprile
- Department of Oncology, San Bortolo Hospital, ULSS8 Berica–East District, Vicenza, Italy
- Department of Oncology, University and General Hospital, Udine, Italy
| | - M Russano
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - S Cereda
- Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - F Leone
- Department of Oncology, University of Turin Medical School/Piedmont Foundation for Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy
| | - S Lonardi
- Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - L Fornaro
- Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Italy
| | - M Scartozzi
- Medical Oncology, Hospital & University of Cagliari, Italy
| | - N Silvestris
- Medical Oncology Unit, Cancer Institute ``Giovanni Paolo II'', 70124 Bari, Italy
| | - S Barni
- Medical Oncology Unit, ASST Bergamo Ovest, Piazzale Ospedale 1, 24047 Treviglio, Bergamo, Italy
| | - F Pantano
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - B Vincenzi
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - A Palloni
- Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| | - G Frega
- Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| | - M Casagrande
- Department of Oncology, University and General Hospital, Udine, Italy
| | - L Ferrari
- Department of Oncology, University and General Hospital, Udine, Italy
| | - V Dadduzio
- Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - R Intini
- Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - R Filippi
- Department of Oncology, University of Turin Medical School/Piedmont Foundation for Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy
| | - E Vasile
- Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Italy
| | - C Vivaldi
- Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Italy
| | - L Faloppi
- Medical Oncology, Hospital of Macerata, Macerata, Italy & Medical Oncology, University of Cagliari, Italy
| | - O Brunetti
- Medical Oncology Unit, Cancer Institute ``Giovanni Paolo II'', 70124 Bari, Italy
| | - M Reni
- Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - M Aglietta
- Department of Oncology, University of Turin Medical School/Piedmont Foundation for Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy
| | - G Tonini
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| |
Collapse
|
18
|
Bajetta E, Celio L, Zilembo N, Bono A, Galluzzo D, Zampino MG, Longhi A, Ferrari L, Buzzoni R. Ovarian Function Suppression with the Gonadotrophin-Releasing Hormone (GnRH) Analogue Goserelin in Premenopausal Advanced Breast Cancer. Tumori 2018; 80:28-32. [PMID: 8191594 DOI: 10.1177/030089169408000105] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and background Goserelin is a gonadotrophin-releasing hormone (GnRH) analogue that induces the suppression of gonadal steroidogenesis, and it could therefore be a medical alternative to irreversible surgical castration. We report the clinical and endocrine results from 40 goserelin-treated premenopausal patients with advanced breast cancer. Methods A depot formulation of the drug (3.6 mg s.c.) was administered fortnightly for the first 4 doses, and monthly thereafter. Gonadotrophins and estradiol (E2) levels were measured before and at specific times during the treatment. Results Objective responses were observed in 17 of the 38 evaluable patients (45%), six of whom achieved complete remission. The best responses were observed on soft tissues (65%). Castration E2 levels were achieved in all of the patients. Conclusions Our results confirm that goserelin is as effective as surgical oophorectomy in premenopausal advanced breast cancer.
Collapse
Affiliation(s)
- E Bajetta
- Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Affiliation(s)
- E Seregni
- Nuclear Medicine Division, National Cancer Institute, Milan, Italy
| | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
A combination of mitomycin C and vinblastine was administered as salvage treatment in 44 patients with heavily pretreated refractory breast cancer. Response rate was 23% (10 of 44) including one complete response of lung metastases. The highest response rate was seen in intrathoracic localizations (45 %). Median duration of response was 6.5 months (range, 3–17). Treatment was generally well tolerated, and only 25 % of patients developed nausea and vomiting. Neurologic toxicity was represented by paresthesia (8 patients) and constipation (one patient). Mild leukopenia was observed in 30 of 172 treatment cycles, but it exceeded grade 2 in only 5 patients. Considering the good compliance of this regimen and the poor prognosis of patients with advanced refractory disease, the combination of mitomycin C plus vinblastine appears to be useful as salvage treatment for metastatic breast cancer.
Collapse
Affiliation(s)
- C Brambilla
- Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
| | | | | | | |
Collapse
|
21
|
Abstract
Bladder cancer shows extreme variability in its behavior. Even the superficial forms, when surgically treated, are characterized by a high recurrence rate, and therefore regular and intensive post-treatment monitoring is an important aspect of the management of this tumor. The standard follow-up of patients with a bladder cancer history is based on cystoscopic examination of the internal bladder, which is an invasive procedure causing discomfort to the patient. In this context, the availability of a non-invasive laboratory test which measures circulating markers associated with bladder cancer could facilitate the monitoring of patients and could be of help in understanding the metastatic potential of bladder tumors, especially the superficial forms.
Collapse
Affiliation(s)
- C Botti
- Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano
| | | | | | | | | | | |
Collapse
|
22
|
Botti C, Seregni E, Menard S, Tagliabue E, Bonanate A, Cantarella D, Lombardo C, Massaron S, Martinetti A, Ferrari L, Ghirelli C, Aiello P, Bombardieri E. Production of a Novel Monoclonal Antibody against Muc4 Mucin. Int J Biol Markers 2018. [DOI: 10.1177/172460089701200108] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- C. Botti
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - E. Seregni
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - S. Menard
- Department of Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - E. Tagliabue
- Department of Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - A. Bonanate
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - D. Cantarella
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - C. Lombardo
- Department of Immunohematology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - S. Massaron
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - A. Martinetti
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - L. Ferrari
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - C. Ghirelli
- Department of Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - P. Aiello
- Department of Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - E. Bombardieri
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| |
Collapse
|
23
|
Cassata A, Procoplo G, Alù M, Ferrari L, Ferrario E, Beretta E, Longarini R, Busto G, De Candis D, Bajetta E. Capecitabine: Indications and Future Perspectives in the Treatment of Metastatic Colorectal and Breast Cancer. Tumori 2018; 87:364-71. [PMID: 11989587 DOI: 10.1177/030089160108700602] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Fluoropyrimidines remain the most important drugs in the treatment of breast and colorectal carcinoma, but response rates and survival time have been disappointing. Optimal administration is by continuous intravenous infusion, which makes it cumbersome to use and compromises patient independence. Recently, a number of new agents, including fluorouracil prodrugs and selective dihydropyrimidine dehydrogenase inhibitors, have been studied, with promising results. Capecitabine is the first in a new class of fluoropyrimidines. It is an oral, tumor-activated anticancer drug whose activity mimics that of continuously infused 5-fluorouracil. Capecitabine circumvents dihydropyrimidine dehydrogenase catabolism and appears to be at least as active against metastatic colorectal and breast cancer as conventionally administered intravenous 5-fluorouracil, with significantly less toxicity, an improved quality of life, and lesser cost. Capecitabine may ultimately provide enhanced antitumor activity to fluorouracil-containing regimes for advanced colorectal and breast cancer.
Collapse
Affiliation(s)
- A Cassata
- Medical Oncology Unit B, National Cancer Institute, Milan, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Martinetti A, Seregni E, Bajetta E, Bolelli G, Ferrari L, Massaron S, Botti C, Bombardieri E. Development of a Rapid and Ultrasensitive RIA Method for Estrogen (E2, E1, E1-S) Determination with Selective Solid Phase Extraction. Int J Biol Markers 2018. [DOI: 10.1177/172460089701200303] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The inhibition of the proliferative stimulation exercised by estrogens on neoplastic cells is the goal of all endocrine therapies in breast cancer. Under various circumstances, e.g. with the use of aromatase inhibitors, this result can be obtained by blocking the synthetic pathway and, consequently, by lowering the circulating levels of estradiol (E2), estrone (E1), and estrone sulfate (E1-S). The evaluation of these hormones in plasma could therefore represent a useful indicator of the biological efficacy of the therapy. However, the measurement of circulating steroids in a large series of patients is often a complicated procedure. Indirect methods of extraction are time consuming and expensive while the analytical sensitivity of direct methods is not sufficient to measure the residual levels of E2, E1, and E1-S. In this paper we describe a novel extraction method for the evaluation of plasma levels of E2, E1, and E1-S. This new method consists of solid phase extraction followed by a highly specific radioimmunoassay. The sensitivity of the assay is 0.6 pg/ml, 2.0 pg/ml and 7.0 pg/ml for E2, E1, and E1-S, respectively.
Collapse
Affiliation(s)
- A. Martinetti
- Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | - E. Seregni
- Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | - E. Bajetta
- Medical Oncology Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | - G.F. Bolelli
- CNR, Reproductive Medicine Unit, Department of Obstetrics and Gynecology, Policlinico S. Orsola, Bologna - Italy
| | - L. Ferrari
- Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | - S. Massaron
- Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | - C. Botti
- Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | - E. Bombardieri
- Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| |
Collapse
|
25
|
Ferrari L, Seregni E, Martinetti A, Van Graafeiland B, Nerini-Molteni S, Botti C, Artale S, Cresta S, Bombardieri E. Chromogranin a Measurement in Neuroendocrine Tumors. Int J Biol Markers 2018; 13:3-9. [PMID: 9681293 DOI: 10.1177/172460089801300102] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Neuroendocrine tumors (NETs) are rare neoplasms characterized by a low proliferative index and, in some cases, a favorable prognosis. These tumors often overproduce and release biologically active substances that are responsible for severe syndromes. Tumor marker measurement provides the clinician with useful information for the management of NET patients. The substances released by overproducing tumors are currently used as biomarkers, but there is a need for sensitive markers also for the “biochemically silent” NETs. The most effective and reliable blood marker available today is chromogranin A (CgA). Because of its high sensitivity and specificity, this glycoprotein can be used for the diagnosis, prognosis and follow-up of NETs. Furthermore, CgA measurement can be used for monitoring those tumors not overproducing or releasing any hormones or biological amines. This paper is a synthetic review on the value of CgA in NET management and reports our experiences with CgA measurement in NET patients.
Collapse
Affiliation(s)
- L Ferrari
- Division of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Bajetta E, Del Vecchio M, Vitali M, Martinetti A, Ferrari L, Queirolo P, Sertoli MR, Cainelli T, Cellerino R, Cascinelli N. A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma. Tumori 2018; 87:219-22. [PMID: 11693798 DOI: 10.1177/030089160108700402] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and Background This trial evaluated the feasibility and tol-erability of an immunochemotherapeutic approach that uses cisplatin, vindesine, and dacarbazine (DTIC), or only DTIC, in combination with interferon alpha-2a (IFN-a), in patients with metastatic melanoma, considering the significant toxicity of several different regimens used up to now. Methods Between May 1995 and September 1997, 51 melanoma patients (50 of whom were assessable) entered a multicentric trial and were randomized to receive cisplatin (30 mg/m2 daily for 3 days) + vindesine (2.5 mg/m2 only day 1) + DTIC (250 mg/m2 daily for 3 consecutive days) + IFN-α (3 MIU im 3x/wk continuously) (CVD arm) versus DTIC (800 mg/m2 day 1) + IFN-α (3 MIU im 3x/wk continuously) (DTIC arm). The chemotherapy was recycled every 21 days. Patient reevaluation was performed every two cycles, and the treatment was continued in case of objective response or stabilization of disease. Results We observed 3 complete responses, 2 partial responses and 5 stable diseases in the CVD arm, and 2 partial responses and 4 stabilizations of disease in the DTIC arm. Conclusions We conclude that these chemotherapeutic regimens are well tolerated regimens with modest toxicity. Future trials will be conducted associating the CVD regimen with biological response modifiers (IFN, IL-2) in order to improve the results.
Collapse
Affiliation(s)
- E Bajetta
- Unit of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
Several circulating mucinous markers, including CA 15.3, MCA, CA 459, CASA, and Truquant BR, are secreted products of the polymorphic MUC1 gene, and are used as diagnostic tools in patients with breast cancer. In clinical practice the measurement of the levels of these markers in the blood can give important information on the tumor's response to treatment and its biological behavior during disease monitoring. Since the marker levels reflect the activity of the tumor, it is important to know all factors influencing the production/secretion and the blood concentrations of MUC1 mucin. Recent findings suggest that MUC1 gene expression is regulated by steroid hormones and other substances present in the serum. Such observations are very important not only because of their biological significance but also for their clinical implications, as one approach to breast cancer therapy is based on chemical hormone manipulation. Nevertheless, we have preliminarily demonstrated that endocrine treatment in breast cancer patients does not influence the circulating CA 15.3 serum levels, so changes in marker levels are related only to the clinical evolution of the tumor.
Collapse
Affiliation(s)
- E Seregni
- Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
The concept of the immunological surveillance against neoplastic cells was initially proposed by Erlich in 1909 and later elaborated by Burnet. This hypothesis states that the normal function of the immune system, in particular the cell-mediated immunity, is to recognize and destroy the transformed and proliferating tumor cells. The role of cell-mediated immunity during the first steps of tumorigenesis remains controversial. However, there is certain evidence about its importance in the progression and dissemination of cancer. The frequent immunosuppressed condition of cancer patients at tumor relapse or recurrence of secondary tumors is a clinical sign supporting this hypothesis, and many studies have demonstrated a defective immune response in patients diagnosed with advanced cancer. Several mechanisms of escape from the immune surveillance have been described, including the immunoselection of tumor antigen-negative variants, the downregulation of MHC class I expression, suppressive T cells, and the elaboration of immunosuppressive cytokines and other factors. Because of the technical difficulty of isolating the very small amounts from culture supernatants or body fluids, only a few of these substances have been characterized and studied with respect to their biological activity: transforming growth factor-β (TGF-β), the protein p15E, interleukin 10 (IL-10), prostaglandin E2 (PGE2), mucins, suppressive E-receptor (SER), immunosuppressive acidic protein (IAP), and adhesion molecules. The possibility of monitoring cancer patients by testing biochemical factors related to cancer growth led to a proposal to measure a number of these factors as tumor markers. Some of them, e.g mucins, enjoy the consensus of the oncologic community, as for some indications they can help the clinician in the management of cancer patients. Except for the class of mucins, the other above-mentioned immunosuppressive factors have not found any clinical application in the laboratory routine because the information deriving from their measurement, although of speculative and scientific interest, has limited clinical value at present. Nevertheless, even if they have no impact on patient management, these substances do have a potential role to play in the study of cancer patients, and should be taken into account when developing new therapeutic strategies.
Collapse
Affiliation(s)
- C Botti
- Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | | | | | | | | |
Collapse
|
29
|
Martinetti A, Seregni E, Ripamonti C, Ferrari L, De Conno F, Miceli R, Pallotti F, Coliva A, Biancolini D, Bombardieri E. Serum Levels of Tartrate-Resistant Acid Phosphatase-5B in Breast Cancer Patients Treated with Pamidronate. Int J Biol Markers 2018; 17:253-8. [PMID: 12521129 DOI: 10.1177/172460080201700406] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A novel immunoassay specific for the osteoclast-produced TRAP isoform 5b has been developed recently. By means of this assay we studied the usefulness of serum TRAP-5b in monitoring the response to palliative treatment with pamidronate in breast cancer patients with bone metastases. We correlated serum TRAP-5b levels with pain intensity and intake of analgesics to assess the possible utility of the marker in identifying patients who could benefit from pamidronate treatment. Twenty-eight advanced breast cancer patients with bone metastases entered the study. Patients were treated according to the following schedule: two two-week cycles of 60 mg/week pamidronate IV, with a three-week interval in between (six infusions over seven weeks), followed by one infusion every three weeks for a total of 24 infusions over a treatment period of 61 weeks. Blood samples were taken before the start of treatment and before each infusion during two treatment cycles. To measure serum TRAP levels we employed the new immunoassay kit BoneTRAP® produced by Suomen Bioanalytiikka Oy (SBA), Oulu, Finland. In order to assess the usefulness of this marker in evaluating the response to pamidronate treatment we divided patients into two groups (group A, worsened; group B, improved) with respect to pain trend and analgesic intake. Our results did not show any statistically significant difference in baseline serum TRAP levels in the two groups. However, one week after the first pamidronate infusion TRAP-5b serum levels decreased by 39% and 18% in groups A and B, respectively (p=0.01); these levels persisted throughout the treatment period. In conclusion, a decrease in TRAP-5b serum levels may reflect the pharmacological activity of pamidronate and seems to predict pain relief and a reduction in analgesic consumption.
Collapse
Affiliation(s)
- A Martinetti
- Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Ferrari L, Seregni E, Lucignani G, Bajetta E, Martinetti A, Aliberti G, Pallotti F, Procopio G, Torre SD, Luksch R, Bombardieri E. Accuracy and Clinical Correlates of Two Different Methods for Chromogranin A Assay in Neuroendocrine Tumors. Int J Biol Markers 2018. [DOI: 10.1177/172460080401900407] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Measurement of chromogranin A (CgA) plays a major role in the management of neuroendocrine tumors (NET); however, reliable assaying of CgA is made difficult by the rapid hydrolysis following its release into the bloodstream. This study was aimed at the assessment of two assays for CgA in NET patients. CgA was measured in 93 patients by means of an enzyme-linked immunosorbent assay (ELISA) and an immunoradiometric assay (IRMA). The specificity and sensitivity of CgA were evaluated in relation to tumor histology. The clinical accuracy of the two assays was evaluated by receiver-operating characteristic (ROC) curve analysis. Regression analysis demonstrated different immunoreactivity for CgA of the antibodies used in the two kits (r=0.61). The two assays had different accuracy also in classifying patients according to their clinical condition (91% vs 64% specificity and 79% vs 79% sensitivity for the ELISA and IRMA assay, respectively) and tumor histology (81% vs 85% sensitivity for the ELISA and IRMA assays, respectively, in carcinoids; 92% vs 67% sensitivity for the ELISA and IRMA assays, respectively, in pancreatic islet cell tumors). The different clinical accuracy of the two assays was confirmed by the ROC analysis (AUC=0.90 vs AUC=0.87 for the ELISA and IRMA assays, respectively). In conclusion, because of the poor standardization of the commercially available measurement tools the clinical accuracy of CgA measurement depends on the assay used. This makes it difficult to compare CgA values measured with different kits and affects the clinical accuracy of the different assays for CgA.
Collapse
Affiliation(s)
- L. Ferrari
- Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | - E. Seregni
- Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | - G. Lucignani
- Institute of Radiological Sciences, University of Milan and Unit of Molecular Imaging, Division of Radiation Therapy, European Institute of Oncology, Milan - Italy
| | - E. Bajetta
- Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | - A. Martinetti
- Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | - G. Aliberti
- Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | - F. Pallotti
- Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | - G. Procopio
- Institute of Radiological Sciences, University of Milan and Unit of Molecular Imaging, Division of Radiation Therapy, European Institute of Oncology, Milan - Italy
| | - S. Della Torre
- Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | - R. Luksch
- Pediatric Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | - E. Bombardieri
- Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| |
Collapse
|
31
|
Moras P, Bihlmayer G, Vescovo E, Sheverdyaeva PM, Papagno M, Ferrari L, Carbone C. Spin-polarized confined states in Ag films on Fe(1 1 0). J Phys Condens Matter 2017; 29:495806. [PMID: 29091051 DOI: 10.1088/1361-648x/aa9760] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Spin- and angle-resolved photoemission spectroscopy of thin Ag(1 1 1) films on ferromagnetic Fe(1 1 0) shows a series of spin-polarized peaks. These features derive from Ag sp-bands, which form quantum well states and resonances due to confinement by a spin-dependent interface potential barrier. The spin-up states are broader and located at higher binding energy than the corresponding spin-down states at [Formula: see text], although the differences attenuate near the Fermi level. The spin-down states display multiple gap openings, which interrupt their parabolic-like dispersion. First-principles calculations attribute these findings to the symmetry- and spin-selective hybridization of the Ag states with the exchange-split bands of the substrate.
Collapse
Affiliation(s)
- P Moras
- Istituto di Struttura della Materia, Consiglio Nazionale delle Ricerche, 34149 Trieste, Italy
| | | | | | | | | | | | | |
Collapse
|
32
|
Pedersen NP, Ferrari L, Venner A, Wang JL, Abbott SBG, Vujovic N, Arrigoni E, Saper CB, Fuller PM. Supramammillary glutamate neurons are a key node of the arousal system. Nat Commun 2017; 8:1405. [PMID: 29123082 PMCID: PMC5680228 DOI: 10.1038/s41467-017-01004-6] [Citation(s) in RCA: 105] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Accepted: 08/10/2017] [Indexed: 12/27/2022] Open
Abstract
Basic and clinical observations suggest that the caudal hypothalamus comprises a key node of the ascending arousal system, but the cell types underlying this are not fully understood. Here we report that glutamate-releasing neurons of the supramammillary region (SuMvglut2) produce sustained behavioral and EEG arousal when chemogenetically activated. This effect is nearly abolished following selective genetic disruption of glutamate release from SuMvglut2 neurons. Inhibition of SuMvglut2 neurons decreases and fragments wake, also suppressing theta and gamma frequency EEG activity. SuMvglut2 neurons include a subpopulation containing both glutamate and GABA (SuMvgat/vglut2) and another also expressing nitric oxide synthase (SuMNos1/Vglut2). Activation of SuMvgat/vglut2 neurons produces minimal wake and optogenetic stimulation of SuMvgat/vglut2 terminals elicits monosynaptic release of both glutamate and GABA onto dentate granule cells. Activation of SuMNos1/Vglut2 neurons potently drives wakefulness, whereas inhibition reduces REM sleep theta activity. These results identify SuMvglut2 neurons as a key node of the wake−sleep regulatory system. Supramammillary nucleus (SuM) neurons have been studied in the context of REM sleep but their possible role in mediating wakefulness is not known. Here the authors elucidate the distinct functional contributions of three subpopulations in the SuM on electrographical and behavioral arousal in mice using genetically targeted approaches.
Collapse
Affiliation(s)
- Nigel P Pedersen
- Department of Neurology and Epilepsy Service, Emory University, Atlanta, GA, 30322, USA.
| | - Loris Ferrari
- Department of Neurology, Beth Israel Deaconess Medical Center, Bostan, MA, 02215, USA.,Division of Sleep Medicine, Harvard Medical School, Bostan, MA, 02215, USA
| | - Anne Venner
- Department of Neurology, Beth Israel Deaconess Medical Center, Bostan, MA, 02215, USA.,Division of Sleep Medicine, Harvard Medical School, Bostan, MA, 02215, USA
| | - Joshua L Wang
- Department of Neurology, Beth Israel Deaconess Medical Center, Bostan, MA, 02215, USA
| | - Stephen B G Abbott
- Department of Neurology, Beth Israel Deaconess Medical Center, Bostan, MA, 02215, USA
| | - Nina Vujovic
- Division of Sleep Medicine, Harvard Medical School, Bostan, MA, 02215, USA
| | - Elda Arrigoni
- Department of Neurology, Beth Israel Deaconess Medical Center, Bostan, MA, 02215, USA.,Division of Sleep Medicine, Harvard Medical School, Bostan, MA, 02215, USA
| | - Clifford B Saper
- Department of Neurology, Beth Israel Deaconess Medical Center, Bostan, MA, 02215, USA.,Division of Sleep Medicine, Harvard Medical School, Bostan, MA, 02215, USA
| | - Patrick M Fuller
- Department of Neurology, Beth Israel Deaconess Medical Center, Bostan, MA, 02215, USA. .,Division of Sleep Medicine, Harvard Medical School, Bostan, MA, 02215, USA.
| |
Collapse
|
33
|
Kaur S, Wang JL, Ferrari L, Thankachan S, Kroeger D, Venner A, Lazarus M, Wellman A, Arrigoni E, Fuller PM, Saper CB. A Genetically Defined Circuit for Arousal from Sleep during Hypercapnia. Neuron 2017; 96:1153-1167.e5. [PMID: 29103805 DOI: 10.1016/j.neuron.2017.10.009] [Citation(s) in RCA: 96] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Revised: 09/11/2017] [Accepted: 10/04/2017] [Indexed: 12/21/2022]
Abstract
The precise neural circuitry that mediates arousal during sleep apnea is not known. We previously found that glutamatergic neurons in the external lateral parabrachial nucleus (PBel) play a critical role in arousal to elevated CO2 or hypoxia. Because many of the PBel neurons that respond to CO2 express calcitonin gene-related peptide (CGRP), we hypothesized that CGRP may provide a molecular identifier of the CO2 arousal circuit. Here, we report that selective chemogenetic and optogenetic activation of PBelCGRP neurons caused wakefulness, whereas optogenetic inhibition of PBelCGRP neurons prevented arousal to CO2, but not to an acoustic tone or shaking. Optogenetic inhibition of PBelCGRP terminals identified a network of forebrain sites under the control of a PBelCGRP switch that is necessary to arouse animals from hypercapnia. Our findings define a novel cellular target for interventions that may prevent sleep fragmentation and the attendant cardiovascular and cognitive consequences seen in obstructive sleep apnea. VIDEO ABSTRACT.
Collapse
Affiliation(s)
- Satvinder Kaur
- Department of Neurology, Program in Neuroscience, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Joshua L Wang
- Department of Neurology, Program in Neuroscience, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Loris Ferrari
- Department of Neurology, Program in Neuroscience, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Stephen Thankachan
- Department of Psychiatry, Harvard Medical School & VA Boston Healthcare, 1400 VFW Parkway, West Roxbury, MA, USA
| | - Daniel Kroeger
- Department of Neurology, Program in Neuroscience, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Anne Venner
- Department of Neurology, Program in Neuroscience, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Michael Lazarus
- International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Japan
| | - Andrew Wellman
- Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Elda Arrigoni
- Department of Neurology, Program in Neuroscience, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Patrick M Fuller
- Department of Neurology, Program in Neuroscience, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Clifford B Saper
- Department of Neurology, Program in Neuroscience, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
34
|
Mariani G, Galli G, Cavalieri S, Valagussa P, Bianchi G, Capri G, Cresta S, Ferrari L, Damian S, Duca M, de Braud F, Moliterni A. Long term results of ASTER study, a single Institution phase II trial of sequential chemotherapy (CT) for operable breast cancer (BC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Balduzzi A, Dalle JH, Jahnukainen K, von Wolff M, Lucchini G, Ifversen M, Macklon KT, Poirot C, Diesch T, Jarisch A, Bresters D, Yaniv I, Gibson B, Willasch AM, Fadini R, Ferrari L, Lawitschka A, Ahler A, Sänger N, Corbacioglu S, Ansari M, Moffat R, Dalissier A, Beohou E, Sedlacek P, Lankester A, De Heredia Rubio CD, Vettenranta K, Wachowiak J, Yesilipek A, Trigoso E, Klingebiel T, Peters C, Bader P. Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group. Bone Marrow Transplant 2017; 52:1406-1415. [PMID: 28737775 DOI: 10.1038/bmt.2017.147] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Revised: 05/31/2017] [Accepted: 06/04/2017] [Indexed: 12/14/2022]
Abstract
Fertility preservation is an urgent challenge in the transplant setting. A panel of transplanters and fertility specialists within the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the International BFM Study Group provides specific guidelines. Patients and families should be informed of possible gender- and age-specific cryopreservation strategies that should be tailored according to the underlying disease, clinical condition and previous exposure to chemotherapy. Semen collection should be routinely offered to all postpubertal boys at the diagnosis of any disease requiring therapy that could potentially impair fertility. Testicular tissue collection might be offered to postpubertal boys; nevertheless, its use has been unsuccessful to date. Oocyte collection after hormonal hyperstimulation should be offered to postpubertal girls facing gonadotoxic therapies that could be delayed for the 2 weeks required for the procedure. Ovarian tissue collection could be offered to pre-/post-pubertal girls. Pregnancies have been reported after postpubertal ovarian tissue reimplantation; however, to date, no pregnancy has been reported after the reimplantation of prepubertal ovarian tissue or in vitro maturation of pre-/post-pubertal ovarian tissue. Possible future advances in reproductive medicine could change this scenario. Health authorities should prioritize fertility preservation projects in pediatric transplantation to improve patient care and quality of life.
Collapse
Affiliation(s)
- A Balduzzi
- Clinica Pediatrica, Università degli Studi di Milano Bicocca, Fondazione Monza e Brianza per il Bambino e la sua Mamma, Ospedale San Gerardo, Monza, Italy
| | - J-H Dalle
- Hemato-Immunology Department, Robert-Debre Hospital, APHP and Paris-Diderot University, Paris, France
| | - K Jahnukainen
- Division of Hematology-Oncology and Stem Cell Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - M von Wolff
- Division of Reproductive Medicine and Endocrinology, Department of Obstetrics and Gynecology, Inselspital Bern, University Hospital, Bern, Switzerland
| | - G Lucchini
- Bone Marrow Transplant Department, Great Ormond Street Hospital, London, UK
| | - M Ifversen
- Department of Pediatric and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - K T Macklon
- The Fertility Clinic, Copenhagen University Hospital, Copenhagen, Denmark
| | - C Poirot
- Adolescent and Young Adult Hematology Unit, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris, University Pierre et Marie Curie, Paris, France
| | - T Diesch
- Department of Pediatric Hematology/Oncology, University Children's Hospital of Basel, Basel, Switzerland
| | - A Jarisch
- Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital, Goethe University Frankfurt am Main, Frankfurt, Germany
| | - D Bresters
- Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands
| | - I Yaniv
- Pediatric Hematology Oncology, Schneider Children's Medical Center of Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - B Gibson
- Department of Paediatric Haematology, Royal Hospital for Children, Scotland, UK
| | - A M Willasch
- Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital, Goethe University Frankfurt am Main, Frankfurt, Germany
| | - R Fadini
- Centro di Medicina della Riproduzione Biogenesi, Istituti Clinici Zucchi, Monza, Italy
| | - L Ferrari
- Department of Gynecology and Obstetrics, Ospedale San Gerardo di Monza, Monza, Italy
| | - A Lawitschka
- St Anna Children's Hospital, UKKJ, MUW, Vienna, Austria
| | - A Ahler
- Division of Reproductive Medicine and Endocrinology, Department of Obstetrics and Gynaecology, University Hospital, Basel, Switzerland
| | - N Sänger
- Division of Reproductive Medicine, Endocrinology and Infertility, Department of Obstetrics and Gynecology, University Hospital, JW Goethe University, Frankfurt, Germany
| | - S Corbacioglu
- Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Hospital, University of Regensburg, Regensburg, Germany
| | - M Ansari
- Department of Pediatrics, Hémato-Oncologie Pédiatrique, CANSEARCH Research Laboratory, Université de Médecine de Genève, Geneva, Switzerland
| | - R Moffat
- Division of Reproductive Medicine and Endocrinology, Department of Obstetrics and Gynaecology, University Hospital, Basel, Switzerland
| | - A Dalissier
- EBMT Paris Office, Hospital Saint Antoine, Paris, France
| | - E Beohou
- EBMT Paris Office, Hospital Saint Antoine, Paris, France
| | - P Sedlacek
- Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic
| | - A Lankester
- Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands
| | - C D De Heredia Rubio
- Pediatric Oncology and Hematology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - K Vettenranta
- Division of Hematology-Oncology and Stem Cell Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - J Wachowiak
- Department of Pediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznan, Poland
| | - A Yesilipek
- Bahcesehir University School of Medicine, Department of Pediatrics, Pediatric Stem Cell Transplantation Unit, Istanbul, Turkey
| | - E Trigoso
- Paediatric Oncology Unit, Paediatric Transplant Unit, Polytechnic and University Hospital 'LA FE', Valencia, Spain
| | - T Klingebiel
- Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital, Goethe University Frankfurt am Main, Frankfurt, Germany
| | - C Peters
- St Anna Children's Hospital, UKKJ, MUW, Vienna, Austria
| | - P Bader
- Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital, Goethe University Frankfurt am Main, Frankfurt, Germany
| |
Collapse
|
36
|
Cazzaniga ME, Airoldi M, Arcangeli V, Artale S, Atzori F, Ballerio A, Bianchi GV, Blasi L, Campidoglio S, Ciccarese M, Cursano MC, Piezzo M, Fabi A, Ferrari L, Ferzi A, Ficorella C, Frassoldati A, Fumagalli A, Garrone O, Gebbia V, Generali D, La Verde N, Maur M, Michelotti A, Moretti G, Musolino A, Palumbo R, Pistelli M, Porpiglia M, Sartori D, Scavelli C, Schirone A, Turletti A, Valerio MR, Vici P, Zambelli A, Clivio L, Torri V. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. Breast 2017; 35:115-121. [PMID: 28711793 DOI: 10.1016/j.breast.2017.06.043] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Revised: 06/12/2017] [Accepted: 06/29/2017] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. PATIENTS AND METHODS This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. RESULTS From July 2013 to December 2015, the EVA study enrolled 404 pts. Median age was 61 years (33-83). Main metastatic sites were: bone (69.1%), soft tissue (34.7%) and viscera (33.2%). Median number of previous treatments was 2 (1-7). 43.3% of the pts had received Fulvestrant. Median exposure to EVE was 31.0 weeks (15.4-58.3) in the whole population. No difference was observed in terms of EVE exposure duration according to DI (p for trend = 0.27) or type of previous treatments (p = 0.33). ORR and Disease Control Rate (DCR) were observed in 31.6% and 60.7% of the patients, respectively, with the lowest ORRs confined in CHT pre-treated patients or in those who received the lowest DI of EVE. Grade 3-4 adverse events (AEs) were reported in 37.9% of the patients. Main AEs were: stomatitis (11.2%), non-infectious pneumonitis - NIP (3.8%), anaemia (3.8%) and fatigue (3.2%). CONCLUSIONS The EVA study provided new insights in the use of EVE-EVE combination in HR+ ABC pts many years after the publication of the pivotal trial. The combination is safe and the best response could be obtained in patients receiving the full dose of EVE and/or after hormone-therapy as Fulvestrant in ABC.
Collapse
Affiliation(s)
- M E Cazzaniga
- Research Unit Phase I Trials, ASST Monza, Monza, Italy; Oncology Unit, ASST Monza, Monza, Italy.
| | - M Airoldi
- Oncology Unit 2 - Città della Salute e della Scienza di Torino, Torino, Italy
| | - V Arcangeli
- Oncology Unit Rimini Azienda USL Romagna, Rimini, Italy
| | - S Artale
- Oncology Department, Ospedale di Gallarate ASST Valle Olona, Gallarate, Italy
| | - F Atzori
- Oncology Unit, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy
| | - A Ballerio
- Oncology Unit, ASST della Valle Olona - Presidio Ospedaliero di Saronno, Saronno, Italy
| | - G V Bianchi
- Oncology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - L Blasi
- Oncology Unit, ARNAS Civico Palermo, Palermo, Italy
| | - S Campidoglio
- Oncology Unit, Ospedale Sacro Cuore di Gesù, Fatebenefratelli, Benevento, Italy
| | - M Ciccarese
- Oncology Unit, Ospedale "Vito Fazzi" di Lecce, Lecce, Italy
| | - M C Cursano
- Oncology Unit, Università Campus Bio-Medico, Roma, Italy
| | - M Piezzo
- National Cancer Institute "Fondazione Giovanni Pascale", Napoli, Italy
| | - A Fabi
- Oncology Unit 1, Istituto Regina Elena - IFO, Roma, Italy
| | - L Ferrari
- Oncology Unit, ASL di Frosinone Osp. "SS. Trinità", Italy
| | - A Ferzi
- Oncology Unit, ASST OVEST Milanese - Presidio di Legnano, Legnano, Italy
| | - C Ficorella
- Dipartimento di Scienze Cliniche Applicate e Biotecnologiche (DISCAB) - Università Degli Studi Dell'Aquila, L'Aquila, Italy
| | - A Frassoldati
- Oncology Unit, Az Ospedaliero Universitaria di Ferrara, Ferrara, Italy
| | - A Fumagalli
- Oncology Unit, Ospedale Moriggia Pelascini, Gravedona, Italy
| | - O Garrone
- Oncology Unit, A.O. S. Croce e Carle Ospedale di Insegnamento, Cuneo, Italy
| | - V Gebbia
- Oncology Unit, Osp. La Maddalena, Palermo, Italy
| | | | - N La Verde
- Oncology Unit, ASST Fatebenefratelli Sacco, Milano, Italy
| | - M Maur
- Oncology and Haematology Department, A.O.U Policlinico di Modena, Modena, Italy
| | - A Michelotti
- Oncology Unit I, Ospedale S. Chiara, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | - G Moretti
- Oncology Unit, IRCCS Arcispedale S. Maria Nuova, Reggio Emilia, Italy
| | - A Musolino
- Oncology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
| | - R Palumbo
- Oncology Unit, IRCCS ICS Maugeri, Pavia, Italy
| | - M Pistelli
- Oncology Unit, AOU Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi, Ancona, Italy
| | - M Porpiglia
- Oncology Unit, Presidio Ospedaliero S. Anna, Torino, Italy
| | - D Sartori
- Oncology Unit, AULSS 3, Mirano, Italy
| | - C Scavelli
- Oncology Unit, Ospedale "S. Cuore di Gesù", Gallipoli, Italy
| | - A Schirone
- Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - A Turletti
- Oncology Unit, Ospedale Martini della ASL "Città di Torino", Torino, Italy
| | - M R Valerio
- Oncology Department, Policlinico di Palermo Paolo Giaccone, Palermo, Italy
| | - P Vici
- Oncology Unit, Istituto Nazionale Tumori Regina Elena - IFO, Roma, Italy
| | - A Zambelli
- Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
| | - L Clivio
- IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy
| | - V Torri
- IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy
| | | | | |
Collapse
|
37
|
Wannesson B, Remaggi G, Intile D, Ferrari L, Cruset S, Fernández I, Miodosky M, Cugliari M, Bordone J, Pavlovsky M. High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma (HL). Hematol Oncol 2017. [DOI: 10.1002/hon.2439_61] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | - G. Remaggi
- Hematology; FUNDALEU; Buenos Aires Argentina
| | - D. Intile
- Hematology; FUNDALEU; Buenos Aires Argentina
| | - L. Ferrari
- Hematology; FUNDALEU; Buenos Aires Argentina
| | - S. Cruset
- Hematology; Hospital El Cruce; Buenos Aires Argentina
| | | | - M. Miodosky
- Hematology; Instituto de Oncologia Angel H. Roffo; Buenos Aires Argentina
| | - M.S. Cugliari
- Hematology; Instituto de Oncologia Angel H. Roffo; Buenos Aires Argentina
| | - J. Bordone
- Hematology; Hospital El Cruce; Buenos Aires Argentina
| | | |
Collapse
|
38
|
|
39
|
Ossana NA, Eissa BL, Baudou FG, Castañé PM, Soloneski S, Ferrari L. Multibiomarker response in ten spotted live-bearer fish Cnesterodon decemmaculatus (Jenyns, 1842) exposed to Reconquista river water. Ecotoxicol Environ Saf 2016; 133:73-81. [PMID: 27414258 DOI: 10.1016/j.ecoenv.2016.06.046] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Revised: 05/31/2016] [Accepted: 06/29/2016] [Indexed: 06/06/2023]
Abstract
The aim of this paper is to assess the water quality to chemical pollution at Roggero Dam, the headwater of the Reconquista river, and to perform a Cadmium (Cd) contamination pulse simulation through a wide battery of biomarkers which included: genotoxicity and enzymatic biomarker parameters on a neotropical teleost fish namely Cnesterodon decemmaculatus. Water samples were taken in order to determine the river's physicochemical profile. An integrative approach was applied using a biomarker index. The bioassay involved the use of laboratory culture adult animals, acclimatized in moderately hard water (MHW) and fed ad libitum. A semi-static 96h bioassay was conducted and the experimental groups were as follows: [1] river water (Rg); [2] river water + 2mg/L Cd (RgCd); [3] MHW + 2mg/L Cadmium (Cd), positive metal control; [4] MHW + 5mg/L Cyclophosphamide (positive genotoxicity control -CP); [5] MWH, negative control (NC). At the end of the exposure time fishes were sectioned and the following biomarkers were determined: 1) condition factor rate (CF); 2) for the anterior section (A) (head): glutathione (GSH) and protein (Pr) content; 3) for the body midsection (M) (viscera): Pr, GSH, Glutathione-S-transferase (GST), catalase (CAT) and superoxide dismutase (SOD). Blood samples were also taken from the fish specimens to estimate the frequency of micronuclei (MN) as well as other nuclear abnormalities (NA). The physicochemical profile of the river water sample indicated high Copper concentrations. CAT and SOD activity and total Pr content did not show any significant changes. GST activity decreased in fish exposed to Rg, while GSH content decreased significantly for all treatments compared to controls in MHW. These results would seem to point to a reduction in cell defense capability as a result of the depletion antioxidants such as GSH. The NA frequency increased significantly in all treated groups while MN frequency was increased only in Cd and CP groups. Using some the biomarkers measured, a biomarker index was estimated which revealed that fish exposed to Rg were 90% affected or highly affected, while those exposed to RgCd were 80% and Cd 68% affected or highly affected. The obtained results indicate the usefulness of the use of a battery of variables by means of the biomarker index to analyze water quality.
Collapse
Affiliation(s)
- N A Ossana
- Department of Basic Sciences and Institute of Ecology and Sustainable Development (PRODEA-INEDES), National University of Lujan, P.O. Box 221, B6700ZBA Luján, Argentina; National Scientific and Technical Research Council (CONICET), Rivadavia 1917, C1033AAJ Buenos Aires, Argentina.
| | - B L Eissa
- Department of Basic Sciences and Institute of Ecology and Sustainable Development (PRODEA-INEDES), National University of Lujan, P.O. Box 221, B6700ZBA Luján, Argentina
| | - F G Baudou
- Department of Basic Sciences and Institute of Ecology and Sustainable Development (PRODEA-INEDES), National University of Lujan, P.O. Box 221, B6700ZBA Luján, Argentina; ANPCyT, Argentina
| | - P M Castañé
- Department of Basic Sciences and Institute of Ecology and Sustainable Development (PRODEA-INEDES), National University of Lujan, P.O. Box 221, B6700ZBA Luján, Argentina
| | - S Soloneski
- National Scientific and Technical Research Council (CONICET), Rivadavia 1917, C1033AAJ Buenos Aires, Argentina; Faculty of Natural Sciences and Museum, National University of La Plata-UNLP, Argentina
| | - L Ferrari
- Department of Basic Sciences and Institute of Ecology and Sustainable Development (PRODEA-INEDES), National University of Lujan, P.O. Box 221, B6700ZBA Luján, Argentina; Scientific Research Commission (CIC)-La Plata, Argentina
| |
Collapse
|
40
|
Ferrari L, Gerratana L, Jove M, Bonotto M, Cinausero M, Twelves C, Puglisi F. Clinical decision making in patients with metastatic breast sancer in the United Kingdom (UK) and Italy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Cremolini C, Antoniotti C, Loupakis F, Bergamo F, Ferrari L, Grande R, Tonini G, Masi G, Schirripa M, Bonotto M, Soldà C, Lucchesi S, rossini D, Corsi D, Ronzoni M, Llimpe FR, Fontanini G, Boni L, Zagonel V, Falcone A. Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.11] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Casagrande M, Cremolini C, Zucchelli G, Bergamo F, Ferrari L, Pietrantonio F, Lonardi S, Loupakis F, Masi G, Pella N, Intini R, Salvatore L, Tomasello G, Pagani F, Pellino A, Dell'Aquila E, Ginocchi L, Milione M, Fea E, Pellegrinelli A, Falcone A. FOLFOXIRI plus bevacizumab (bev) as upfront treatment for metastatic colorectal cancer (mCRC) patients (pts) with initially unresectable liver-limited disease (LLD). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
43
|
Filipazzi V, Ferrari L, De Masi P, Cattaneo M, Latocca M, Fasola C, Dalu D, Piazza E. Maintenance treatment with pemetrexed in NSCLC. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Aprile G, Fanotto V, Vivaldi C, Fontanella C, Bordonaro R, Leone F, Rimassa L, Rosati G, Pasquini G, Tomasello G, Ferrari L, Santini D, Giampieri R, Pietrantonio F, Cordio S, Filippi R, Bozzarelli S, Caparello C, Fornaro L. Characteristics and outcomes of advanced gastric cancer patients treated with at least three lines of chemotherapy: analysis on 300 Italian real-world cases. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw333.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Ongaro E, Bonotto M, Gerratana L, Casagrande M, Ferrari L, Iacono D, Garattini S, Fanotto V, Basile D, Cattaneo M, Rihawi K, Giovannoni M, Pella N, Ermacora P, Cardellino G, Aprile G, Fasola G. May mutational status influence the metastatic pattern of colorectal cancer patients? Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Ferrari L, Gerratana L, Jove M, Bonotto M, Cinausero M, Iacono D, Fontanella C, Bozza C, Fanotto V, Basile D, Pelizzari G, Vitale M, Minisini A, Mansutti M, Russo S, Andreetta C, Fasola G, Puglisi F, Twelves C. Treatment strategies in patients with Metastatic Breast Cancer: real-world practice in the United Kingdom (UK) and Italy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Paliy M, Trebicky T, Guo Q, Kobe B, Suhan N, Arsenault G, Ferrari L, Yang J. Nonmonotonic piezoresistive effect in elastomeric composite films. J Appl Polym Sci 2016. [DOI: 10.1002/app.43518] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- M. Paliy
- Mechanical and Materials Engineering; Western University; London Ontario Canada N6A 5B9
- Surface Science Western; Western University; London Ontario Canada N6A 5B9
| | - T. Trebicky
- Mechanical and Materials Engineering; Western University; London Ontario Canada N6A 5B9
- Surface Science Western; Western University; London Ontario Canada N6A 5B9
| | - Q. Guo
- Mechanical and Materials Engineering; Western University; London Ontario Canada N6A 5B9
| | - B. Kobe
- Surface Science Western; Western University; London Ontario Canada N6A 5B9
| | - N. Suhan
- Lanxess, Inc.; London Ontario Canada N6G 4X8
| | | | - L. Ferrari
- Lanxess, Inc.; London Ontario Canada N6G 4X8
| | - J. Yang
- Mechanical and Materials Engineering; Western University; London Ontario Canada N6A 5B9
| |
Collapse
|
48
|
Casagrande M, Moretto R, Loupakis F, Cremolini C, Masi G, Borelli B, Lonardi S, Marsico Valentina A, Salvatore L, Rossini D, Ferrari L, Ricci V, Grande R, Tomasello G, Ronzoni M, Allegrini G, Tonini G, Mancini M, Zaniboni A, Chiara S, Carlomagno C, Falcone A. PD-009 Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Di Maggio G, Santangelo R, Guerrieri S, Ferrari L, Vitali F, Medaglini S, Rodegher M, Colombo B, Moiola L, Del Carro U, Martinelli V, Comi G, Leocani L. 12. Sensitivity and predictive value of OCT and VEP in multiple sclerosis. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2015.09.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
50
|
Huang S, Ferrari L, Coppi E, Vitali F, Magnani G, Comi G, Leocani L. Retinal ganglion cell layer correlates with cognitive involvement in Alzheimer’s disease and mild cognitive impairment. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2015.11.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|